Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Peak Bio, Inc.

Peak Bio, Inc. develops innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Peak Bio Inc. | 789 followers on LinkedIn. Clinical-stage biopharmaceutical company. #PKBO | Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Notice to recruiters

All recruitment vendors (temporary staffing agencies, placement services, and professional recruiters) are prohibited from contacting our employees.

In order to be an authorized vendor partner for Peak Bio, all such organizations must have a formal written agreement with Peak Bio’s Human Resources Department. 

pH Pharma Inc. Director

신용남

Associate Director at pH Pharma Co., Ltd.

	Dec '21	Dec '22	Dec '23
account payables	301.47K -	3.62M 1,100.13%	5.86M 62.03%
accumulated other comprehensive income loss	88.44K -	29.52K 66.62%	93.63K 217.19%
cash and cash equivalents	205.48K -	654.89K 218.72%	381.65K 41.72%
cash and short term investments	205.48K -	654.89K 218.72%	381.65K 41.72%
common stock	1.72K -	1.98K 15.27%	2.31K 16.89%
deferred revenue		4.86M -
deferred revenue non current
deferrred tax liabilities non current	35K -
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt		3.51M -
long term investments
net debt	-205.48K -	4.95M 2,507.89%	8.46M 70.93%
net receivables
other assets
other current assets	253.67K -	2.58T 1,015,457,445.07%	1.99M 100.00%
other current liabilities	2.49M -	231.30K 90.71%	5.82M 2,416.97%
other liabilities
other non current assets	238.50K -	241.20K 1.13%	69.20K 71.31%
other non current liabilities	186.57K -	1.32M 605.26%	230.65K 82.47%
othertotal stockholders equity	6.43M -	17.22M 167.85%	19.92M 15.67%
preferred stock
property plant equipment net	380.61K -	4.06M 966.11%	153.11K 96.23%
retained earnings	-8.45M -	-25.35M 199.80%	-38.17M 50.60%
short term debt		2.10M -	8.84M 321.83%
short term investments
tax assets
tax payables	107.47K -
total assets	1.08M -	7.53M 598.32%	2.60M 65.52%
total current assets	459.15K -	3.23M 603.65%	2.37M 26.52%
total current liabilities	2.79M -	10.80M 286.87%	20.52M 90.01%
total debt		5.60M -	8.84M 57.76%
total investments
total liabilities	3.01M -	15.62M 418.47%	20.75M 32.83%
total liabilities and stockholders equity	1.08M -	7.53M 598.32%	2.60M 65.52%
total non current assets	619.11K -	4.30M 594.37%	222.31K 94.83%
total non current liabilities	221.57K -	4.82M 2,076.77%	230.65K 95.22%
total stockholders equity	-1.94M -	-8.09M 318.26%	-18.16M 124.31%

COM:PEAK-BIO

Peak Bio, Inc.

Last Close

0.05

14/11 20:00

Market Cap

192.60K

Beta: -

Volume Today

1.93K

Avg: -

Preview